SOLARA — Solara Active Pharma Sciences Share Price
- IN₹24.74bn
- IN₹32.98bn
- IN₹12.89bn
- 40
- 22
- 55
- 31
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 15.66 | ||
PEG Ratio (f) | 0.35 | ||
EPS Growth (f) | 82.58% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.25 | ||
Price to Tang. Book | 3.57 | ||
Price to Free Cashflow | 28.09 | ||
Price to Sales | 1.92 | ||
EV to EBITDA | 68.38 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -4.17% | ||
Return on Equity | -19.82% | ||
Operating Margin | -4.06% |
Financial Summary
Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 13,217.5 | 16,168.8 | 12,683.4 | 14,438.1 | 12,889.2 | 15,364 | 16,805 | -1.45% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +59.01 | +48.92 | n/a | n/a | n/a | n/a | +82.58 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Solara Active Pharma Sciences Limited is an India-based global, pureplay active pharmaceutical ingredients (API) company. The Company is engaged in the manufacturing and development of APIs and offers contract manufacturing and development services for global companies. Its commercial product category includes Albendazole, Aprepitant (Antiemetic), Colchicine, Citicoline Sodium, Disulfiram, Dolutegravir, Etomidate, Flucytosine, Ibuprofen Arginine, Lurasidone Hydrochloride, Rifaximin, Tioconazole, Zileuton and others. Its research and development (R&D) product category includes Brivaracetam, Flecainide Acetate, Naproxen Base, Obeticholic acid, Patiromer Sorbitex Calcium, Rotigotine, Safinamide, Sapropterin, Sugammadex, Tranexamic Acid, Sucroferric Oxyhydroxide and others. Its business is spread across 70 countries with operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa. It has one R&D center in Chennai.
Directors
- Deepak Vaidya NEC (76)
- Rajender Rao CEO
- Subhash Anand CFO
- Rajesh Salwan COO
- Sudhir Nambiar CSO
- S. Murali Krishna CCO
- V. Sundara Moorthy OTH
- Ankur Thadani NED (37)
- Nirmal Bhogilal IND
- Ronald de Vries IND
- Vineeta Rai IND (76)
- Ramakrishnan Rajagopal IND
- Kausalya Santhanam IND
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 23rd, 2017
- Public Since
- June 27th, 2018
- No. of Shareholders
- 73,912
- No. of Employees
- 2,156
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India
- Shares in Issue
- 48,053,022

- Address
- 3rd & 4th Floor, Batra Centre, CHENNAI, 600032
- Web
- https://solara.co.in/
- Phone
- +91 4443446700
- Contact
- Suddapalli Krishna
- Auditors
- Deloitte Haskins & Sells LLP
Upcoming Events for SOLARA
Q1 2026 Solara Active Pharma Sciences Ltd Earnings Release
Solara Active Pharma Sciences Ltd Annual Shareholders Meeting
Q2 2026 Solara Active Pharma Sciences Ltd Earnings Release
Similar to SOLARA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 23:21 UTC, shares in Solara Active Pharma Sciences are trading at IN₹508.85. This share price information is delayed by 15 minutes.
Shares in Solara Active Pharma Sciences last closed at IN₹508.85 and the price had moved by -1.53% over the past 365 days. In terms of relative price strength the Solara Active Pharma Sciences share price has underperformed the S&P BSE 100 Index by -7.24% over the past year.
The overall consensus recommendation for Solara Active Pharma Sciences is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSolara Active Pharma Sciences does not currently pay a dividend.
Solara Active Pharma Sciences does not currently pay a dividend.
Solara Active Pharma Sciences does not currently pay a dividend.
To buy shares in Solara Active Pharma Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹508.85, shares in Solara Active Pharma Sciences had a market capitalisation of IN₹24.74bn.
Here are the trading details for Solara Active Pharma Sciences:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SOLARA
Based on an overall assessment of its quality, value and momentum Solara Active Pharma Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Solara Active Pharma Sciences is IN₹559.46. That is 9.95% above the last closing price of IN₹508.85.
Analysts covering Solara Active Pharma Sciences currently have a consensus Earnings Per Share (EPS) forecast of IN₹17.80 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Solara Active Pharma Sciences. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -29.67%.
As of the last closing price of IN₹508.85, shares in Solara Active Pharma Sciences were trading -22.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Solara Active Pharma Sciences PE ratio based on its reported earnings over the past 12 months is 15.66. The shares last closed at IN₹508.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Solara Active Pharma Sciences' management team is headed by:
- Deepak Vaidya - NEC
- Rajender Rao - CEO
- Subhash Anand - CFO
- Rajesh Salwan - COO
- Sudhir Nambiar - CSO
- S. Murali Krishna - CCO
- V. Sundara Moorthy - OTH
- Ankur Thadani - NED
- Nirmal Bhogilal - IND
- Ronald de Vries - IND
- Vineeta Rai - IND
- Ramakrishnan Rajagopal - IND
- Kausalya Santhanam - IND